Nice | Idelalisib for treating chronic lymphocytic leukaemia

15th February 2016 by Louise Hudman

Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a ‘first-in-class’ drug which inhibits enzymes involved in cell proliferation, death and migration.

Side-effects

Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I've tried simple templates or hard copies of locum packs before but find they so quickly become out of date. I like the way the NASGP's Standardised Practice Information Portal is easier to navigate and update than these paper-based systems."

Dr Amy Kerstein

See the full list of features within our NASGP membership plans

Membership